The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CURX | N/A | N/A | N/A | -93% |
| S&P | +13.95% | +78.35% | +12.25% | +7% |
No news articles found for Curanex Pharmaceuticals.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$15.44K | 0.0% |
| Market Cap | $20.39M | 0.0% |
| Net Income | -$954.06K | -854.6% |
| EBITDA | -$935.89K | -816.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.83M | 2286.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $61.15K | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -17.05% | 0.0% |
| Return On Invested Capital | -51.88% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9,187.02K | -6970.2% |
| Operating Free Cash Flow | -$9,187.02K | -6970.1% |
| Metric | Q3 2025 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Book | 65.45 | - | |||
| Price to Tangible Book Value | 65.44 | - | |||
| Enterprise Value to EBITDA | -15.64 | - | |||
| Return on Equity | -128.3% | -85.2% | -17.3% | - | |
| Total Debt | $0.00K | $291.18K | $476.45K | $61.15K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
